Home ›
Leukemia Trials ›
NCT04793919
Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia
The trial is open to all patients with a diagnosis of acute promyelocytic leukemia (APL) who are PCR-positive for the PML-RARα transcript and less than 18 years of age.
Trial Details
NCT ID NCT04793919
Phase PHASE2
Sponsor Associazione Italiana Ematologia Oncologia Pediatrica
Status RECRUITING
Cancer Type Leukemia
Interventions Mylotarg Arsenic Trioxide All-trans retinoic acid
Locations (sample) Brussels, Belgium|50.85045,4.34878 Prague, Czechia|50.08804,14.42076 Aarhus N, Denmark|56.20367,10.17317 Bordeaux, France|44.84124,-0.58046 Essen, Germany|51.45657,7.01228
Key Eligibility Criteria
Newly diagnosed APL confirmed by the presence of PML/RARα fusion gene Age \<18 years Written informed consent by parents or legal guardians
For full eligibility, visit ClinicalTrials.gov .
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Leukemia Trials on Trialify →